Studies of fetal wounds, which heal without scarring, have revealed different growth factor profiles in the embryo and fetus from those of adult wounds.
6 In particular, low levels of transforming growth factor (TGF)-β, a potent stimulator of the scarring response in adults, are found in the fetus. Numerous publications have established the pivotal role of TGF-β in wound healing.
7 8 9 TGF-β is a potent stimulator for connective tissue formation during wound repair.
10 11 It stimulates fibroblast proliferation,
12 extracellular matrix synthesis,
13 and decreases extracellular matrix degradation.
8 Therefore, inhibiting the actions of TGF-β is an attractive strategy for therapeutic modulation of scarring in the body. More recent attention has turned to the role of connective tissue growth factor (CTGF) which is regulated downstream from TGF-β.
13 During wound repair, TGF-β mRNA is coordinately expressed with that of CTGF.
14 15 Both TGF-β and CTGF are overexpressed in various fibrotic conditions.
16 The findings that TGF-β increases CTGF synthesis and that TGF-β and CTGF share many biological functions, such as fibroblast activation and stimulation of extracellular matrix protein production,
17 are consistent with the hypothesis that CTGF is a downstream mediator of TGF-β.
9 However, although TGF-β has been found to play a central role in fibroblast-to-myofibroblast differentiation
3 4 and to induce the matrix contraction involved in scarring,
18 the involvement of CTGF in these events is not clear, despite the coexpression of these growth factors during wound healing.